Opportunity Information: Apply for PA 09 024
Apply for PA 09 024
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Erythropoiesis Stimulating Agents and Tumor Progression (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Nov 6, 2008 and posted on Nov 6, 2008.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Special district governments Small businesses Private institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts For profit organizations other than small businesses City or township governments State governments.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI) funding opportunity PA-09-024, titled "Erythropoiesis Stimulating Agents and Tumor Progression (R21)," supports exploratory research aimed at clarifying how erythropoietin (EPO) and related erythropoiesis-stimulating agents (ESAs) influence cancer biology. ESAs have a long clinical history in treating anemia, particularly anemia associated with renal failure, and they have also been used to manage anemia in patients receiving chemotherapy. The scientific concern driving this announcement is that multiple clinical trials raised red flags suggesting ESA administration in some cancer settings may be linked to faster tumor progression and higher mortality. Because these clinical outcomes have major implications for patient safety and treatment guidelines, the FOA emphasizes the need for rigorous mechanistic studies that explain whether, when, and how ESAs might affect tumor cell growth, survival, and disease progression.
The central research focus is on understanding the biology of ESAs in the tumor context, especially their effects on tumor cell proliferation and apoptosis (programmed cell death). In practical terms, projects proposed under this FOA would be expected to investigate how EPO/ESAs interact with tumor cells and the tumor microenvironment, what signaling pathways or receptors may be involved, and what downstream cellular behaviors are altered as a result. The intent is to move beyond conflicting clinical observations by generating clearer experimental evidence about causality and mechanism. The broader goal is to support high-quality research that can help interpret past clinical trial findings and guide safer clinical use of ESAs in oncology.
This announcement uses the NIH Exploratory/Developmental Grant (R21) mechanism, which is designed for early-stage, high-impact, and potentially higher-risk studies that can open up new directions or provide preliminary data for later, more comprehensive work. The FOA runs in parallel with a companion announcement of the same scientific scope that uses the R01 mechanism (PA-09-023), giving applicants a choice between an exploratory R21 approach and a more traditional full-scale research project format, depending on the maturity and breadth of their proposed work.
In terms of funding parameters, the listed award ceiling is $200,000, and there is no cost sharing or matching requirement. The number of awards was not predetermined and depended on funding availability and the number of meritorious applications received, meaning competition and award volume would vary by cycle. The opportunity was posted on November 6, 2008, with an original and final closing date of January 7, 2012, and it was archived on February 7, 2012.
Eligibility was broad and included many organization types across the public, private, nonprofit, and governmental spectrum. Eligible applicants included nonprofits with and without 501(c)(3) status (other than institutions of higher education), public and state-controlled institutions of higher education, private institutions of higher education, small businesses, for-profit organizations other than small businesses, and a range of government entities such as state governments, county governments, city or township governments, special district governments, and independent school districts. The FOA also allowed additional categories, including eligible federal agencies, faith-based and community-based organizations, Hispanic-serving institutions, non-U.S. entities (foreign organizations), and regional organizations. Programmatically, it falls under NIH and aligns with CFDA areas 93.393 (Cancer Cause and Prevention Research) and 93.396 (Cancer Biology Research), reflecting its emphasis on tumor biology and cancer outcomes.
For applicants or institutions needing the full text or technical help accessing the announcement, the FOA pointed to the NIH Office of Extramural Research (OER) resources and provided an OER webmaster contact, along with an online link to the funding announcement page.
Frequently Asked Questions (FAQs): PA-09-024 - Erythropoiesis Stimulating Agents and Tumor Progression (R21)
1) What is the funding opportunity PA-09-024?
PA-09-024 is a National Cancer Institute (NCI) funding opportunity titled "Erythropoiesis Stimulating Agents and Tumor Progression (R21)." It supports exploratory research focused on clarifying how erythropoietin (EPO) and related erythropoiesis-stimulating agents (ESAs) may influence cancer biology, including tumor progression.
2) Which agency is offering this opportunity?
The opportunity is offered by the National Cancer Institute (NCI) under the National Institutes of Health (NIH).
3) What is the main purpose of this FOA?
The purpose is to fund rigorous mechanistic studies to explain whether, when, and how ESAs might affect tumor cell growth, survival, and disease progression, helping interpret conflicting clinical trial observations and supporting safer clinical use of ESAs in oncology.
4) Why is this research area considered important?
The FOA is driven by concerns from multiple clinical trials that raised red flags suggesting ESA administration in some cancer settings may be associated with faster tumor progression and higher mortality. Because these potential outcomes directly affect patient safety and treatment guidelines, the FOA emphasizes the need for clear experimental evidence about causality and biological mechanism.
5) What types of agents are covered under this FOA?
The FOA focuses on erythropoietin (EPO) and related erythropoiesis-stimulating agents (ESAs), which have been used clinically to treat anemia (including anemia associated with renal failure) and to manage anemia in patients receiving chemotherapy.
6) What scientific questions are projects expected to address?
Projects are expected to explore how EPO/ESAs interact with tumor cells and the tumor microenvironment, including what receptors or signaling pathways may be involved and what downstream cellular behaviors change as a result.
7) What are the central biological outcomes of interest?
The FOA highlights tumor cell proliferation and apoptosis (programmed cell death) as central areas of interest in understanding ESA effects in the tumor context.
8) Is this FOA focused on clinical trials or on mechanism?
Based on the description provided, the FOA emphasizes mechanistic studies that move beyond conflicting clinical observations by generating clearer experimental evidence about causality and mechanism in tumor biology.
9) What grant mechanism does PA-09-024 use?
PA-09-024 uses the NIH Exploratory/Developmental Grant (R21) mechanism, which is intended for early-stage, potentially higher-risk, high-impact studies that can open new research directions or provide preliminary data for later, more comprehensive work.
10) Is there a related funding opportunity for larger or more mature projects?
Yes. The FOA runs in parallel with a companion announcement with the same scientific scope that uses the R01 mechanism: PA-09-023. Applicants could choose between the exploratory R21 approach and a more traditional full-scale R01 format, depending on the maturity and breadth of the work.
11) What is the award ceiling for this opportunity?
The listed award ceiling is $200,000.
12) Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
13) How many awards were expected to be made?
The number of awards was not predetermined. Awards depended on funding availability and the number of meritorious applications received, so award volume could vary by cycle.
14) When was this opportunity posted?
The opportunity was posted on November 6, 2008.
15) What were the closing dates for applications?
The FOA listed an original and final closing date of January 7, 2012.
16) Is this FOA still active?
No. The opportunity was archived on February 7, 2012.
17) Who was eligible to apply?
Eligibility was broad and included organizations across the public, private, nonprofit, and governmental spectrum, including:
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Small businesses
- For-profit organizations other than small businesses
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
18) Were any additional applicant categories allowed?
Yes. The FOA also allowed additional categories including eligible federal agencies, faith-based and community-based organizations, Hispanic-serving institutions, non-U.S. entities (foreign organizations), and regional organizations.
19) Can non-U.S. (foreign) organizations apply?
Yes. The FOA explicitly included non-U.S. entities (foreign organizations) among the allowed applicant categories.
20) What NIH/CFDA program areas does this opportunity align with?
The FOA aligns with CFDA areas 93.393 (Cancer Cause and Prevention Research) and 93.396 (Cancer Biology Research), reflecting its emphasis on tumor biology and cancer outcomes.
21) What is the broader goal of the funded research?
The broader goal is to support high-quality mechanistic research that can help interpret past clinical trial findings and guide safer clinical use of ESAs in oncology.
22) Where could applicants get the full text or technical help for this FOA?
The FOA pointed applicants to NIH Office of Extramural Research (OER) resources for the full text and technical help accessing the announcement, and referenced an OER webmaster contact and an online link to the funding announcement page.
Browse more opportunities from the same category: Education Health
Next opportunity: Region 1 Request for Initial Proposals for EPA/Regional Dedicated Water Quality Program Funding
Previous opportunity: Erythropoiesis Stimulating Agents and Tumor Progression (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 024
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 024) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Cancer Institute Program Project (P01) Applications Apply for PAR 09 025 Funding Number: PAR 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) Apply for PAR 09 026 Funding Number: PAR 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Education Programs of Excellence in Scientifically Validated Behavioral Treatment (R25) Apply for RFA MH 09 110 Funding Number: RFA MH 09 110 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Shared Instrumentation Grant Program (S10) Apply for PAR 09 028 Funding Number: PAR 09 028 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Mutant Mouse Regional Resource Centers (Limited Competition U42) Apply for RFA RR 09 003 Funding Number: RFA RR 09 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Mutant Mouse Regional Resource Centers (U42) Apply for RFA RR 09 002 Funding Number: RFA RR 09 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| STUDIES OF ENERGY BALANCE AND CANCER IN HUMANS Apply for PA 04 124 Funding Number: PA 04 124 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellows (F31) in Nursing Research Apply for PAR 05 091 Funding Number: PAR 05 091 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| IDeA Networks of Biomedical Research Excellence (INBRE) P20 Apply for PAR 08 150 Funding Number: PAR 08 150 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) Apply for PAR 08 225 Funding Number: PAR 08 225 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for the Year 2008 and 2009 (P50) Apply for PAR 08 020 Funding Number: PAR 08 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| National Cooperative Drug Discovery and Development Groups (NCDDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01/U19) Apply for PAR 08 238 Funding Number: PAR 08 238 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01) Apply for PAR 08 245 Funding Number: PAR 08 245 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomedical Technology Research Resource (P41) Apply for PAR 08 259 Funding Number: PAR 08 259 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diversity promoting Institutions Drug Abuse Research Program (DIDARP) (R24) Apply for PAR 09 011 Funding Number: PAR 09 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium (Limited Competition) U01 Apply for RFA CA 09 503 Funding Number: RFA CA 09 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) Apply for RFA DA 09 012 Funding Number: RFA DA 09 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Education Grants for Statistical Training in the Genetics of Addiction (R25) Apply for PAR 08 081 Funding Number: PAR 08 081 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR R44) Apply for RFA CA 08 021 Funding Number: RFA CA 08 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR AREA for Health Disparities Research at Minority Serving Institutions (MSIs ) (R15) Apply for PA 08 171 Funding Number: PA 08 171 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 024", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.